Lilly: Cialis samples posted after rep dated request forms (AUTH/1926/12/06)

📅 2006 | 🖉 Dr Anzal Qurbain
📊

Key facts

Case numberAUTH/1926/12/06
ComplainantGeneral practitioner
CompanyEli Lilly and Company Limited
ProductCialis (tadalafil)
IssueSamples received by post via an agency; disputed request/signatures; rep dated request forms
Complaint received6 December 2006
Case completed14 February 2007
Applicable Code year2006
Breach clausesClause 17.3
No breach clauses consideredClauses 2, 9.1, 15.2, 17.10
SanctionUndertaking received
AppealNo appeal

Download the full case report (PDF)


Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI
🎬 Expert Video Walkthrough
🎬
Video walkthrough — coming for members
Subscribe now and get expert video analysis for every case as we publish them.
Subscribe — from £299/yr
📋

What happened

  • A general practitioner complained that samples of Cialis (tadalafil) were sent to him by post from an agency.
  • The GP said he had not requested the samples; correspondence suggested the agency said it had signed sample requests for three doctors, but the GP contended the signatures were not those of the doctors.
  • A Lilly representative had left sample request forms at the practice and later collected them from reception.
  • When collecting the forms, the representative completed address details and dated the forms himself, and confirmed with the receptionist which form related to which doctor.
  • Lilly said it and the agency believed the requests were valid and responded in good faith; Lilly asked the practice to investigate the signatures.
⚖️

Outcome

  • Breach: Clause 17.3 (sample request forms must be signed and dated by the applicant; here they were undated when received and dated by the representative).
  • No breach: Clause 17.10 (unsolicited medicines by post) — the Panel considered that, from Lilly’s perspective, the samples had been requested and Lilly responded in good faith.
  • No breach: Clauses 9.1 and 15.2 — despite concerns about overall arrangements, the Panel did not consider rulings warranted.
  • No breach: Clause 2 — circumstances did not warrant the particular censure reserved for Clause 2.
  • No appeal.
🔒

Unlock the full case analysis

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value
£249/year
Annual — save £99
or
£29/mo
Monthly
Join Now — Instant Access

⭐ Business Intelligence Access

See the full compliance picture for every pharma company

291 Company Intelligence Reports — breach patterns, appeal history, industry ranking, PDF export.

Request Access →
⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week — free.

Subscribe Free
🎓 AQP Training